A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1231-1236

  Goddard, C A ^a   Ratcliff, R ^a   Anderson, J R ^b   Glenn, E ^a   Brown, S ^a   Gill, D R ^c   Hyde, S C ^c   MacVinish, L J ^a   Huang, L ^d   Higgins, C F ^c   Cuthbert, A W ^a   Evans, M J ^a   Colledge, W H ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cationic liposome; Cystic fibrosis; Gene therapy; Mouse model

Indexed keywords

CHLORIDE ION; COMPLEMENTARY DNA; CYCLIC AMP; LIPOSOME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLORIDE CURRENT; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; GENE EXPRESSION; GENE TARGETING; INFLAMMATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; TRACHEA;

ANIMALIA;

EID: 9844252876     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300515     Document Type: Article

References (33)

1. Quinton PM. Cystic fibrosis: a disease in electrolyte transport. FASEB J 1990; 4: 2709-2717.
2. Riordan JR et al. Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA. Science 1989; 245: 1066-1073.
3. Yang Y et al. Inactivation of E2A in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
4. Yang Y, Li Q, Ertl H, Wilson J. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
5. Brody SL et al. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gens Ther 1994; 5: 821-836.
6. Yei S et al. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994; 5: 731-744.
7. Dong J et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319-331.
8. Engelhardt J, Litzky L, Wilson J Prolonged transgene expression in cotton rat lung with recombinant adenovirus defective in E2A. Hum Gene Ther 1994; 5: 1217-1229.
9. Nabel EG et al. Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localisation. Hum Gem Ther 1992; 3: 649-656.
10. San H et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781-788.
11. Hyde SC et al. Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 1993; 362: 250-254.
12. Alton EWFW et al. Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet 1993; 5: 135-142.
13. MacVinish LJ et al. Chloride secretion in the trachea of null cystic fibrosis mice: the effects of transfection with pTrial10-CFTR2. J Physiol 1997; 499: 677-687.
14. Caplen NJ et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995; 1: 35-46.
15. Gill DR et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997; 4: 199-209.
16. Ratcliff R et al. Production of a severe cystic fibrosis mutation in mice by gene targeting. Nat Genet 1993; 4: 35-41.
17. Colledge WH et al. Generation and characterisation of a δF508 cystic fibrosis mouse model. Nat Genet 1995; 10: 445-452
18. - secretion in nasal epithelia of CF mice. Am J Physiol 1994; 266: C1478-C1483.
19. 2+ sequestration. FEES Lett 1987; 224: 331-336.
20. 2+ stores. FEES Lett 1990; 274: 214-216.
21. Hay JG, McElvaney NG, Herena J, Crystal RG. Modification of nasal potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 1995; 6: 1487-1496.
22. Crystal RG et al. A phase I study in cystic fibrosis patients of the safety, toxicity and biological efficacy of a single administration of a replication-deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis transmembrane conductance regulator gene in the lung. Hum Gene Ther 1995; 6: 643-666.
23. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 7: 207-216.
24. Zabner J et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996; 97: 1504-1511.
25. Knowles MR et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med 1995; 333: 823-831.
26. Porteous DJ et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Therapy 1997; 4: 210-218.
27. St George JA et al. Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 103-116.
28. Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
29. Zabner J et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
30. Rosenecker J et al. Adenovirus infection in cystic fibrosis patients - implications for the use of adenoviral vectors for gene transfer. Infection 1996; 24: 5-8.
31. Yang Y, Trinchieri G, Wilson J. Recombinant IL-12 prevents formation of blocking IGA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
32. McLachlan G et al. Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Therapy 1996; 3: 1113-1123.
33. Feigner PL et al. Nomenclature for synthetic gene delivery systems. Hum Gene Ther 1997; 8: 511-512.